High-dose Antioxidants for Central Serous Chorioretinopathy
Maneno muhimu
Kikemikali
Tarehe
Imethibitishwa Mwisho: | 11/30/2009 |
Iliyowasilishwa Kwanza: | 08/19/2009 |
Uandikishaji uliokadiriwa Uliwasilishwa: | 08/19/2009 |
Iliyotumwa Kwanza: | 08/20/2009 |
Sasisho la Mwisho Liliwasilishwa: | 12/28/2009 |
Sasisho la Mwisho Lilichapishwa: | 12/29/2009 |
Tarehe halisi ya kuanza kwa masomo: | 11/30/2004 |
Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 11/30/2008 |
Tarehe ya Kukamilisha Utafiti: | 05/31/2009 |
Hali au ugonjwa
Uingiliaji / matibabu
Drug: antioxidants tablets
Awamu
Vikundi vya Arm
Mkono | Uingiliaji / matibabu |
---|---|
Experimental: antioxidant tablets the study arm received antioxidant tablets (Icaps) for 3 months or until the resolution of the disease | |
Placebo Comparator: placebo tablets the control arm received placebo tablets for 3 months or until the resolution of the disease |
Vigezo vya Kustahiki
Zama zinazostahiki Kujifunza | 30 Years Kwa 30 Years |
Jinsia Inastahiki Kujifunza | All |
Hupokea Wajitolea wa Afya | Ndio |
Vigezo | Inclusion Criteria: 1. patients with acute central serous chorioretinopathy within 6 weeks of onset 2. age between 30-50 years 3. new or recurrent attack (the symptom-free period should longer than 6 months) 4. fluorescein angiography (FA) confirmed the diagnosis with the inkblot or smoke-stack leakage and the optical coherence tomography (OCT) showed definite subretinal fluid 5. patients' ability for proper follow up. Exclusion Criteria: 1. chronic central serous chorioretinopathy(longer than 6 weeks) 2. complicated central serous chorioretinopathy such as secondary choroidal neovascularization (CNV) that detected from FA 3. pregnancy, steroid user and patients that contraindicated for high dose antioxidants therapy such as heavy smokers, lung cancer, thyrotoxicosis, renal stone and anemia (hematocrit less than 30%). |
Matokeo
Hatua za Matokeo ya Msingi
1. visual acuity and central macular thickness [6 months]
Hatua za Matokeo ya Sekondari
1. fluorescein leakage at the third month [6 months]